|
|
Effects of plasma exchange combined with continuous renal replacement therapy on acute fatty liver of pregnancy |
Cheng-Bo Yu, Jia-Jia Chen, Wei-Bo Du, Ping Chen, Jian-Rong Huang, Yue-Mei Chen, Hong-Cui Cao and Lan-Juan Li |
Hangzhou, China
Author Affiliations: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine (Yu CB, Chen JJ, Du WB, Chen P, Huang JR, Chen YM, Cao HC and Li LJ); Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (Du WB, Huang JR, Cao HC and Li LJ), Hangzhou 310003, China
Corresponding Author: Lan-Juan Li, MD, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China (Tel: 86-571-87236458; Fax: 86-571-87236459; Email: ljli@zju.edu.cn) |
|
|
Abstract BACKGROUND: Acute fatty liver of pregnancy (AFLP) in the third trimester or early postpartum period can lead to fatal liver damage. Its traditional therapy is not very effective in facilitating hepatic recovery. The safety and effect of plasma exchange (PE) in combination with continuous renal replacement therapy (CRRT) (PE+CRRT) for AFLP still needs evaluation.
METHODS: Five AFLP patients with hepatic encephalopathy and renal failure were subjected to PE+CRRT in our department from 2007 to 2012. Their symptoms, physical signs and results were observed, and all relevant laboratory tests were compared before and after PE+CRRT.
RESULTS: All the 5 patients were well tolerated to the therapy. Four of them responded to the treatment and showed improvement in clinical symptoms/signs and laboratory results, and they were cured and discharged home after the treatment. One patient succeeded in bridging to transplantation for slowing down hepatic failure and its complications process after 2 treatment sessions. Intensive care unit stay and hospital stay were 9.4 (range 5-18) and 25.0 days (range 11-42), respectively.
CONCLUSION: PE+CRRT is safe and effective and should be used immediately at the onset of hepatic encephalopathy and/or renal failure in patients with AFLP.
|
|
|
|
|
|
|
|